PSSR: Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM

Sponsor
Zhejiang University (Other)
Overall Status
Suspended
CT.gov ID
NCT02121405
Collaborator
(none)
350
7
2
124.1
50
0.4

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether primary radiotherapy can be omitted for the locally advanced rectal cancer with Magnetic Resonance Imaging (MRI) negative circumferential margin.

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

The preoperative radiochemotherapy with fluorouracil followed surgery is the standard therapy for patients with locally advanced rectal cancer. However, the necessity of radiotherapy has been questioned for a long time especially for patients with enough circumferential margins. Moreover, indiscriminate radiotherapy will result Irreversible ovarian dysfunction for female. In the past decade, there were two major progresses for colorectal cancer. Firstly, oxaliplatin with fluorouracil has become the standard adjuvant chemotherapy for advanced colon cancer. Oxaliplatin improved the survival of colon cancer patients than single fluorouracil. Our experience showed that oxaliplatin with fluorouracil could improve the prognosis of rectal cancer without radiotherapy. It has been proven that oxaliplatin should not add to radiotherapy for rectal cancer. However, whether oxaliplatin can replace radiotherapy for certain rectal cancer patients is still unknown. Secondly, Magnetic Resonance Imaging (MRI) has been proven that can predict the circumferential margin status for rectal cancer. Now, preoperative MRI scan can recognize the rectal cancer patients with low recurrence risk. The radiotherapy may be omitted to the patients with low recurrence risk. This study is a randomized controlled trial to compare the 3-year disease-free survival (DFS) differences of group of experiment (the patients receive primary surgery followed selective radiochemotherapy) and group of control (the patients receive indiscriminate preoperative radiochemotherapy followed surgery) for locally advanced rectal cancer with negative MRI circumferential margin.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
350 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy Versus Conventional Preoperative Radiochemotherapy for Locally Advanced Rectal Cancer With MRI Negative Circumferential Margin
Actual Study Start Date :
Oct 1, 2015
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Feb 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Primary surgery

The patients receive primary rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME. To patients with pathological confirmed positive circumferential margin (CRM), postoperative concurrent radiochemotherapy is required that starts in 3 months post operation with capecitabine. Capecitabine and Oxaliplatin (CapeOx) chemotherapy starts in 4 weeks post operation to total of 6 cycles/18 weeks. To patients with pathological confirmed negative CRM, radiotherapy is omitted. The stage III patients receive 8 cycles/6 months CapeOx chemotherapy. The stage II patients with low microsatellite instability (MSI) receive 8 cycles/6 months Capecitabine chemotherapy. The stage II patients with high MSI and stage I patients do not receive adjuvant therapy.

Procedure: Rectectomy
Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).

Radiation: Radiotherapy
45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.

Drug: Capecitabine
Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
Other Names:
  • Xeloda
  • Drug: Oxaliplatin
    Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
    Other Names:
  • Eloxatin
  • Active Comparator: Preoperative radiochemotherapy

    All of the patients receive conventional concurrent radiochemotherapy with capecitabine for 5 weeks. Then all of the patients receive 2 cycles/6 weeks capecitabine ± Oxaliplatin chemotherapy. Patients receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with total mesorectal excision 8 weeks post radiotherapy. All of the patients receive 5 cycles/15 weeks capecitabine ± Oxaliplatin adjuvant chemotherapy. The use of Oxaliplatin depends on the doctor's decision.

    Procedure: Rectectomy
    Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).

    Radiation: Radiotherapy
    45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.

    Drug: Capecitabine
    Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
    Other Names:
  • Xeloda
  • Drug: Oxaliplatin
    Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
    Other Names:
  • Eloxatin
  • Outcome Measures

    Primary Outcome Measures

    1. Disease-free survival [Three years from the date of randomization]

    Secondary Outcome Measures

    1. The rate of positive circumferential resection margin [1 day of postoperative pathological examination.]

    2. Quality of life by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C(core) 30 and QLQ-CR(colorectal) 29 forms [Baseline before any treatment,3 months post operation, 1 year post operation]

    3. Overall survival [Five years from the date of randomization]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Rectal adenocarcinoma or mucinous adenocarcinoma that is 6-12 cm from the anal verge.

    • MRI scan confirmed cT3N0 or cT4aN0 or cT1-4aN+ mid rectal cancer (6-12cm from the anal verge).

    • MRI scan confirmed more than 1 mm circumferential margin.

    • Age 18-75 years old.

    • Without distant metastasis.

    Exclusion Criteria:
    • Malignant history.

    • Contraindications of MRI scan.

    • Contraindications of radiotherapy.

    • Contraindications of chemotherapy.

    • Pregnancy.

    • Multidisciplinary team thinks that the patient is unsuitable to take part in research (For example, there are obvious regional lymph nodes involved in low rectal cancer patients who are thought with high risk of recurrence).

    • Refuse to take part in research.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Union Hospital Fujian Medical University Fuzhou Fujian China 350001
    2 Liaoning Cancer Hospital Shenyang Liaoning China 110042
    3 Zhongshan Hospital Fudan University Shanghai Shanghai China 200032
    4 The First Affiliated Hospital of College of Medicine Zhejiang University Hangzhou Zhejiang China 310003
    5 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang China 310016
    6 Jinhua People's Hospital Jinhua Zhejiang China 321000
    7 Yuyao People's Hospital Yuyao Zhejiang China 315400

    Sponsors and Collaborators

    • Zhejiang University

    Investigators

    • Principal Investigator: Ke-Feng Ding, M.D., The Second Affiliated Hospital Zhejiang University Medical School

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Ding Ke-Feng, Professor, Zhejiang University
    ClinicalTrials.gov Identifier:
    NCT02121405
    Other Study ID Numbers:
    • CRCCZ-R01
    First Posted:
    Apr 23, 2014
    Last Update Posted:
    May 11, 2022
    Last Verified:
    May 1, 2022
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 11, 2022